MedImmune spins out autoimmune play Viela

By Elizabeth S. Eaton | Feb 28, 2018 | 7:40 AM GMT

Editor's Note: This article was updated on Feb 28, 2018 at 11:00 PM GMT

MedImmune LLC is spinning out six compounds into severe autoimmune disease play Viela Bio Inc. (Gaithersburg, Md.). Bing Yao, who is head of the AstraZeneca plc (LSE:AZN; NYSE:AZN) subsidiary’s Respiratory, Inflammation & Autoimmunity (RIA) Innovative Medicines unit, will become CEO of the newco. Jorn